PMID- 36127638
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20230823
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Sep 20
TI  - Immune checkpoint inhibitors and their impact on liver enzymes and attenuation.
PG  - 998
LID - 10.1186/s12885-022-10090-9 [doi]
LID - 998
AB  - BACKGROUND: Immune related adverse events impacting the liver are common from 
      immune checkpoint inhibitor (ICI) therapy; however, there is little data 
      regarding the subclinical impact of ICIs on liver inflammation. The study aims to 
      determine whether ICI therapy affects liver attenuation and liver enzymes in 
      melanoma patients with and without hepatic steatosis. METHODS: A retrospective, 
      cohort study was conducted of patients with advanced melanoma treated with ICI 
      therapy who received serial PET-CT scans at the Vanderbilt University Medical 
      Center (VUMC). Primary outcomes included: liver attenuation measured by 
      PET-CT/non-contrast CT and liver enzymes. Hepatic steatosis was diagnosed by 
      radiologists on clinical imaging. RESULTS: Among 839 patients with advanced 
      melanoma treated with ICIs, 81 had serial PET-CT scans approximately 12 months 
      apart and long-term survival; of these 11 patients had pre-existing 
      steatosis/steatohepatitis. Overall, ICI was not associated with significant 
      increases in liver enzymes in all patients; modest decreases in liver enzymes 
      were observed in patients with pre-existing steatosis/steatohepatitis. Similarly, 
      liver attenuation did not change from baseline to post-treatment (58.44 vs 60.60 
      HU, + 2.17, p = 0.055). CONCLUSIONS: ICIs may not chronically affect liver 
      enzymes or liver attenuation, a non-invasive measure of liver fat content and 
      inflammation, in the general population or in those with pre-existing 
      steatosis/steatohepatitis.
CI  - (c) 2022. The Author(s).
FAU - Park, Benjamin C
AU  - Park BC
AD  - Vanderbilt University School of Medicine, Nashville, TN, USA.
AD  - Department of Medicine, Vanderbilt University Medical Center, 2220 Pierce Avenue, 
      777 Preston Research Building, Nashville, TN, 3723, USA.
FAU - Lee, Aaron X T
AU  - Lee AXT
AD  - Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 
      USA.
FAU - Ye, Fei
AU  - Ye F
AD  - Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 
      USA.
FAU - Turker, Isik
AU  - Turker I
AD  - Department of Medicine, Vanderbilt University Medical Center, 2220 Pierce Avenue, 
      777 Preston Research Building, Nashville, TN, 3723, USA.
FAU - Johnson, Douglas B
AU  - Johnson DB
AD  - Department of Medicine, Vanderbilt University Medical Center, 2220 Pierce Avenue, 
      777 Preston Research Building, Nashville, TN, 3723, USA. 
      douglas.b.johnson@vumc.org.
LA  - eng
GR  - T32 CA217834/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20220920
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Cohort Studies
MH  - *Fatty Liver/complications
MH  - Humans
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - Inflammation/complications
MH  - *Melanoma/drug therapy
MH  - Positron Emission Tomography Computed Tomography
MH  - Retrospective Studies
MH  - Tomography, X-Ray Computed/methods
PMC - PMC9487144
OTO - NOTNLM
OT  - Immune checkpoint inhibitors
OT  - Immune related adverse events
OT  - Liver attenuation
OT  - Steatohepatitis
OT  - Steatosis
COIS- The authors declare no potential conflicts of interest.
EDAT- 2022/09/21 06:00
MHDA- 2022/09/24 06:00
PMCR- 2022/09/20
CRDT- 2022/09/20 23:35
PHST- 2022/04/26 00:00 [received]
PHST- 2022/09/05 00:00 [accepted]
PHST- 2022/09/20 23:35 [entrez]
PHST- 2022/09/21 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/09/20 00:00 [pmc-release]
AID - 10.1186/s12885-022-10090-9 [pii]
AID - 10090 [pii]
AID - 10.1186/s12885-022-10090-9 [doi]
PST - epublish
SO  - BMC Cancer. 2022 Sep 20;22(1):998. doi: 10.1186/s12885-022-10090-9.